Siemens Announces Study Results of New Imaging Biomarker

Moving personalized medicine from promise to practice, Siemens Healthcare (www.siemens.com/healthcare) announces the early study findings of a new imaging biomarker for hypoxic tumors. The study, done in collaboration with Dr. Jian Q. (Michael) Yu, and Fox Chase Cancer Center in Philadelphia, was presented today at the World Molecular Imaging Conference in Nice, France. This imaging biomarker is intended for exclusive world wide distribution by PETNET Solutions, a fully owned Siemens subsidiary.

The results of the safety study indicated that HX4, a new imaging biomarker developed at Siemens Molecular Imaging Biomarker Research, is safe for use in human positron emission tomography (PET) imaging studies. The study included initial human data regarding bio-distribution of the new agent, radiation dosimetry levels in normal volunteers and optimal patient imaging parameters with PET. Results of the study indicated that the compound was found to be stable for imaging at 145 minutes post injection, that it would safely clear the body through urinary elimination and that there were very low dose accumulations in major organs.

source: Siemens Healthcare

No comments: